

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/814,555
				Filing Date	March 30, 2004
				First Named Inventor	Matthew D. LINNIK
				Art Unit	1633
				Examiner Name	F. Sajjadi
Sheet	1	of	5	Attorney Docket Number	252312008000

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/F.S./ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	1.	US-2003/0077273-A1	04-24-2003	Linnik et al.	
	2.	US-2004/0224366-A1	11-11-2004	Jones et al.	
	3.	US-2005/0004351-A1	01-06-2005	Marquis et al.	
	4.	US-2005/0026856-A1	02-03-2005	Coutts et al.	
	5.	US-2005/0031635-A1	02-10-2005	Coutts et al.	
	6.	US-2005/0175620-A1	08-11-2005	Jones	
	7.	US-2005/0208480-A1	09-22-2005	Victoria et al.	
	8.	US-2005/0220785-A1	10-06-2005	Engle et al.	
	9.	US-2005/0226844-A1	10-13-2005	Jones	
	10.	US-2006/0142229-A1	06-29-2006	Linnik et al.	
	11.	US-2006/0217333-A1	09-28-2006	Linnik et al.	
	12.	US-2006/0229270-A1	10-12-2006	Linnik	
	13.	US-6,858,210-B1	02-22-2005	Marquis et al.	
	14.	US-6,951,939-B2	10-04-2005	Jones	
	15.	US-7,081,242-B1	07-25-2006	Linnik et al.	
	16.	US-7,138,244-B2	11-21-2006	Barstad et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/F.S./	17.	EP-0 743 856-B1	11-27-1996	The University of Virginia Patent Foundation		
↓	18.	WO-92/05801-A1	04-16-1992	The University of Virginia Patents Foundation		
↓	19.	WO-00/15259-A1	03-23-2000	The University of Virginia Patent Foundation		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/F.S./ ↓ ↓	20.	Aharoni, A. et al. (1993). "Characterization of a Multisubunit Human Protein Which Selectively Binds Single Stranded d(GA) _n and d(GT) _n Sequence Repeats in DNA." <i>Nucl. Acid. Res.</i> 21(22):5221-5228.	
	21.	Ferguson, P. J. et al. (July 1, 1995). "Antigen-Based Heteropolymers Facilitate, Via Primate Erythrocyte Complement Receptor Type 1, Rapid Erythrocyte Binding of an Autoantibody and Its Clearance From The Circulation in Rhesus Monkeys," <i>The Journal of Immunology</i> 155(1):339-347.	
	22.	Food and Drug Administration. (October 13, 2004). Information from United States Food and Drug Administration, 2 pages.	

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	11/05/2007
-----------------------	---------------------	--------------------	------------

pa- 1189943

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/814,555		
		Filing Date	March 30, 2004		
		First Named Inventor	Matthew D. LINNIK		
		Art Unit	1633		
		Examiner Name	F. Sajjadi		
Sheet	2	of	5	Attorney Docket Number	252312008000

/F.S./	23.	Iverson, G.M. et al. (December 1998). "Anti- β 2 Glycoprotein I (β 2GPI) Autoantibodies Recognize an Epitope on the First Domain of β 2GPI," <i>Proc. Natl. Acad. Sci. USA</i> 95:15542-15546.	
	24.	Iverson, G.M. et al. (1998) "A Chemically Defined, Toleragen-Based Approach for Targeting Anti- β 2-glycoprotein I Antibodies," <i>Lupus</i> 7(Suppl 2):S166-S169.	
	25.	Jones, D.S. et al. (1998) "Synthesis of a Cyclic-Thioether Peptide Which Binds Anti-Cardiolipin Antibodies," <i>Tetrahedron Letters</i> 39:6107-6110.	
	26.	Jones, D.S. et al. (1999). "Multivalent Thioether-Peptide Conjugates: B Cell Tolerance of an Anti-Peptide Immune Response," <i>Bioconjugate Chemistry</i> 10(3):480-488.	
	27.	Jones, D.S. et al. (2000). "A Convenient Synthesis of N-(tert-butyloxycarbonyl)aminoxy Ethers," <i>Tetrahedron Letters</i> 41:1531-1533.	
	28.	Jones, D.S. et al. (1994). "A New Oligonucleotide Conjugate for Suppression of Anti-Double Stranded DNA Antibodies," <i>Abstracts of Papers</i> , Part 1, 207 th American Chemical Society National Meeting, San Diego, CA, March 13-17, 1994, Abstract No. BIOT 113.	
	29.	Kandiah, D.A. et al. (1998). "Current Insights into the "Antiphospholipid" Syndrome: Clinical, Immunological, and Molecular Aspects," <i>Advances in Immunology</i> 70:507-563.	
	30.	La Jolla Pharmaceutical Co. (February 16, 2004). "La Jolla Pharmaceutical's New Drug Application for Lupus Drug Candidate Riquent® Accepted for Review by FDA," located at < http://web.archive.org/web/20040919061150/www.prsnewswire.com/cgi-bin/stories.pl?ACCT=105&ST... >, last visited on March 26, 2007, 2 pages.	
	31.	La Jolla Pharmaceutical Co. (February 17, 2004). "La Jolla Pharmaceutical's New Drug Application for Lupus Drug Candidate Riquent® Accepted for Review by FDA San Diego," located at < http://www.ljpc.com/pressrelease/0217_04.html >, last visited on April 9, 2007, 2 pages.	
	32.	La Jolla Pharmaceutical Co. (March 2, 2004). "La Jolla Pharmaceutical Company Reports Fourth Quarter and Year End 2003 Financial Results," located at < http://www.ljpc.com/pressrelease/0302_04.html >, last visited on April 9, 2007, 3 pages.	
	33.	La Jolla Pharmaceutical Co. (March 11, 2004). "La Jolla Pharmaceutical to Present Additional Riquent® Results at SG Cowen Healthcare Conference," located at < http://www.ljpc.com/pressrelease/0311_04.html >, last visited on April 9, 2007, 3 pages.	
	34.	La Jolla Pharmaceutical Co. (April 21, 2004). "La Jolla Pharmaceutical to Present at 7 th International Congress on Systemic Lupus Erythematosus and Related Conditions," located at < http://www.ljpc.com/pressrelease/0421_04.html >, last visited on April 9, 2007, 3 pages.	
	35.	La Jolla Pharmaceutical Co. (May 6, 2004). "La Jolla Pharmaceutical Company Reports First Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0506_04.html >, last visited on April 9, 2007, 2 pages.	
	36.	La Jolla Pharmaceutical Co. (May 10, 2004). "La Jolla Pharmaceutical Data on Riquent® Presented at Lupus Medical Conference," located at < http://www.ljpc.com/pressrelease/0510_04.html >, last visited on April 9, 2007, 3 pages.	
	37.	La Jolla Pharmaceutical Co. (June 10, 2004). "La Jolla Pharmaceutical Presents at European Rheumatology Medical Conference," located at < http://www.ljpc.com/pressrelease/0610_04.html >, last visited on April 9, 2007, 2 pages.	
	38.	La Jolla Pharmaceutical Co. (June 24, 2004). "La Jolla Pharmaceutical Announces Publication of Review Articles Regarding Its Two Drug Candidates," located at < http://www.ljpc.com/pressrelease/0624_04.html >, last visited on April 9, 2007, 3 pages.	
↓	39.	La Jolla Pharmaceutical Co. (August 2, 2004). "La Jolla Pharmaceutical Reaches Agreement with Cardio-Renal Division of FDA Regarding Phase 4 Trial Design Under Special Protocol Assessment," located at < http://www.ljpc.com/pressrelease/0802_04.html >, last visited on July 26, 2005, 3 pages.	

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	11/05/2007
--------------------	---------------------	-----------------	------------

pa- 1189943

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/814,555
			Filing Date	March 30, 2004
			First Named Inventor	Matthew D. LINNIK
			Art Unit	1633
			Examiner Name	F. Sajjadi
			Attorney Docket Number	252312008000
Sheet	3	of	5	

/F.S./	40.	La Jolla Pharmaceutical Co. (August 5, 2004). "La Jolla Pharmaceutical Company Reports Second Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0805_04.html >, last visited on April 9, 2007, 2 pages.	
	41.	La Jolla Pharmaceutical Co. (October 14, 2004). "La Jolla Pharmaceutical Company Receives Letter From FDA About Riquent," located at < http://www.ljpc.com/pressrelease/1014_04.html >, last visited on April 9, 2007, 2 pages.	
	42.	La Jolla Pharmaceutical Co. (October 29, 2004). "La Jolla Pharmaceutical Company Presents at American College of Rheumatology and American Society of Nephrology Annual Meetings," located at < http://www.ljpc.com/pressrelease/1029_04.html >, last visited on April 9, 2007, 3 pages.	
	43.	La Jolla Pharmaceutical Co. (November 4, 2004). "La Jolla Pharmaceutical Company Reports Third Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/1104_04.html >, last visited on April 9, 2007, 2 pages.	
	44.	La Jolla Pharmaceutical Co. (November 23, 2004). "La Jolla Pharmaceutical Company Provides Update on Riquent Program," located at < http://www.ljpc.com/pressrelease/1123_04.html >, last visited on July 26, 2005, 3 pages.	
	45.	La Jolla Pharmaceutical Co. (February 17, 2005). "La Jolla Pharmaceutical Company Presents at BIO CEO & Investor Conference," located at < http://www.ljpc.com/pressrelease/0217_05.html >, last visited on April 9, 2007, 2 pages.	
	46.	La Jolla Pharmaceutical Co. (March 3, 2005). "La Jolla Pharmaceutical Company Reports Fourth Quarter and Year End 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0303_05.html >, last visited on April 9, 2007, 2 pages.	
	47.	La Jolla Pharmaceutical Co. (March 14, 2005). "La Jolla Pharmaceutical Announces Outcome of Recent FDA Discussions," located at < http://www.ljpc.com/pressrelease/0314_05.html >, last visited on July 26, 2005, 2 pages.	
	48.	La Jolla Pharmaceutical Co. (March 30, 2005). "La Jolla Pharmaceutical Restructures Following Recent FDA Discussion," located at < http://www.ljpc.com/pressrelease/0330_05.html >, last visited on April 9, 2007, 3 pages.	
	49.	La Jolla Pharmaceutical Co. (May 5, 2005). "La Jolla Pharmaceutical Company Reports First Quarter 2005 Financial Results," located at < http://www.ljpc.com/pressrelease/0505_05.html >, last visited on April 9, 2007, 2 pages.	
	50.	La Jolla Pharmaceutical Co. (May 31, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent," located at < http://www.ljpc.com/pressrelease/0531_05.html >, last visited on July 26, 2005, 2 pages.	
	51.	La Jolla Pharmaceutical Co. (August 4, 2005). "La Jolla Pharmaceutical Company Reports Second Quarter and Year-to-Date 2005 Financial Results," located at < http://www.ljpc.com/pressrelease/0804_05.html >, last visited on April 9, 2007, 3 pages.	
	52.	La Jolla Pharmaceutical Co. (October 13, 2005). "La Jolla Pharmaceutical Company to Present at BIO Investor Forum 2005," located at < http://www.ljpc.com/pressrelease/1013_05.html >, last visited on April 9, 2007, 2 pages.	
	53.	La Jolla Pharmaceutical Co. (October 18, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent®," located at < http://www.ljpc.com/pressrelease/1018_05.html >, last visited on April 9, 2007, 4 pages.	
	54.	La Jolla Pharmaceutical Co. (November 2, 2005). "La Jolla Pharmaceutical Company To Present at the Rodman & Renshaw Techvest 7 th Annual Healthcare Conference," located at < http://www.ljpc.com/pressrelease/1102_05.html >, last visited on April 9, 2007, 2 pages.	
↓	55.	La Jolla Pharmaceutical Co. (November 14, 2005). "La Jolla Pharmaceutical Company Presents at American College of Rheumatology Annual Scientific Meeting," located at < http://www.ljpc.com/pressrelease/1114_05.html >, last visited on April 9, 2007, 3 pages.	

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	11/05/2007
--------------------	---------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/814,555
				Filing Date	March 30, 2004
				First Named Inventor	Matthew D. LINNIK
				Art Unit	1633
				Examiner Name	F. Sajjadi
Sheet	4	of	5	Attorney Docket Number	252312008000

/F.S./	56.	La Jolla Pharmaceutical Co. (January 11, 2006). "La Jolla Pharmaceutical Company to Initiate Multi-Dose Study of Riquent in Lupus Patients," located at < http://www.ljpc.com/pressrelease/0111_06.html >, last visited on April 10, 2007, 2 pages.	
	57.	La Jolla Pharmaceutical Co. (March 29, 2006). "La Jolla Pharmaceutical Company Presents at National Autoimmune Disease Conference," located at < http://www.ljpc.com/pressrelease/0329_06.html >, last visited on April 10, 2007, 2 pages.	
	58.	La Jolla Pharmaceutical Co. (June 22, 2006). "La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent," located at < http://www.ljpc.com/pressrelease/0622_06.html >, last visited on April 9, 2007, 3 pages.	
	59.	La Jolla Pharmaceutical Co. (August 9, 2006). "La Jolla Pharmaceutical Expands Enrollment in Phase 3 International Riquent® Study," located at < http://www.ljpc.com/pressrelease/0809_06.html >, last visited on April 9, 2007, 4 pages.	
	60.	La Jolla Pharmaceutical Co. (September 27, 2006). "La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent® Study," located at < http://www.ljpc.com/pressrelease/0927_06.html >, last visited on April 9, 2007, 3 pages.	
	61.	La Jolla Pharmaceutical Co. (October 12, 2006). "La Jolla Pharmaceutical Provides Update on MAA Application in Europe," located at < http://www.ljpc.com/pressrelease/1012_06.html >, last visited on April 9, 2007, 3 pages.	
	62.	La Jolla Pharmaceutical Co. (November 6, 2006). "La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent® Study," located at < http://www.ljpc.com/pressrelease/1106_06.html >, last visited on April 9, 2007, 3 pages.	
	63.	La Jolla Pharmaceutical Co. (February 1, 2007). "La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent® Study," located at < http://www.ljpc.com/pressrelease/0201_07.html >, last visited on April 9, 2007, 3 pages.	
	64.	La Jolla Pharmaceutical Co. (March 8, 2007). "La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent® Lupus Phase 3 Trial," located at < http://www.ljpc.com/pressrelease/0308_07.html >, last visited on April 9, 2007, 4 pages.	
	65.	La Jolla Pharmaceutical Co. (March 20, 2007). "La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent® Lupus Phase 3 Trial," located at < http://www.ljpc.com/pressrelease/0320_07_phase_3_results.html >, last visited on April 9, 2007, 3 pages.	
	66.	Linnik, M.D. et al. (2004). "Anti-dsDNA Antibodies and Exacerbation of Renal Disease in Patients with Systemic Lupus Erythematosus: Results From 2 Randomized Controlled Trials [RCTS] with LJP 394," located at < http://www.ljpc.com/abstracts/abstract_2004_15.html >, last visited on August 19, 2005, 2 pages.	
	67.	Linnik, M.D. et al. (2005). "Progressive Reduction in Risk of Renal Flare in SLE Patients is Associated With Improved Long-Term Control of Anti-dsDNA Antibody Levels," located at < http://www.ljpc.com/abstracts/abstract_2005_05.html >, last visited July 29, 2007, 2 pages.	
	68.	Linnik, M.D. et al. (April 2005). "Relationship Between Anti-Double-Stranded DNA Antibodies and Exacerbation of Renal Disease in Patients With Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 52(4):1129-1137.	
	69.	Morimoto, C. et al. (March 1987). "A Defect of Immunoregulatory T Cell Subsets in Systemic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody," <i>J. Clin. Invest.</i> 79:762-768.	
	70.	Office Action mailed on July 18, 2000, for U.S. Patent Application No. 09/457,875, 7 pages.	
	71.	Office Action mailed on October 5, 2001, for U.S. Patent Application No. 09/766,365, 5 pages.	
	72.	Office Action mailed on January 14, 2005, for U.S. Patent Application No. 10/144,391, 11 pages.	
↓	73.	Office Action mailed on February 22, 2005, for U.S. Patent Application No. 10/219,238, 13 pages.	

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	11/05/2007
--------------------	---------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/814,555
				Filing Date	March 30, 2004
				First Named Inventor	Matthew D. LINNIK
				Art Unit	1633
				Examiner Name	F. Sajjadi
Sheet	5	of	5	Attorney Docket Number	252312008000

/F.S./	74.	Office Action mailed on January 30, 2007, for U.S. Patent Application No. 10/748,541, 7 pages.	
	75.	PDRhealth. (Date Unknown). "Lupus Erythematosus," located at < http://www.pdrhealth.com/patient_education/BHG01RH18.shtml >, last visited July 11, 2007, 8 pages.	
	76.	Sern, D.S. et al. (1998). "Structural Characterization and Optimization of Antibody-Selected Phage Library Mimotopes of an Antigen Associated with Autoimmune Recurrent Thrombosis," <i>Biochemistry</i> 37(46):16069-16081.	
	77.	United States Application No. 09/590,592 filed on June 8, 2000, for Jones et al. (Copy not attached)	
	78.	United States Application No. 11/562,174 filed on November 21, 2006, for Strand et al. (Copy not attached)	
	79.	United States Application No. 11/565,467 filed on November 30, 2006, for Linnik et al. (Copy not attached)	
↓	80.	United States Application No. 11/613,987 filed on December 20, 2006, for Linnik. (Copy not attached)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	11/05/2007
--------------------	---------------------	-----------------	------------